These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 2225709)

  • 1. Diazepam metabolism in native Chinese poor and extensive hydroxylators of S-mephenytoin: interethnic differences in comparison with white subjects.
    Zhang YA; Reviriego J; Lou YQ; Sjöqvist F; Bertilsson L
    Clin Pharmacol Ther; 1990 Nov; 48(5):496-502. PubMed ID: 2225709
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Incidence of S-mephenytoin hydroxylation deficiency in a Korean population and the interphenotypic differences in diazepam pharmacokinetics.
    Sohn DR; Kusaka M; Ishizaki T; Shin SG; Jang IJ; Shin JG; Chiba K
    Clin Pharmacol Ther; 1992 Aug; 52(2):160-9. PubMed ID: 1505151
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Importance of genetic factors in the regulation of diazepam metabolism: relationship to S-mephenytoin, but not debrisoquin, hydroxylation phenotype.
    Bertilsson L; Henthorn TK; Sanz E; Tybring G; Säwe J; Villén T
    Clin Pharmacol Ther; 1989 Apr; 45(4):348-55. PubMed ID: 2495208
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of the interaction potential of a new proton pump inhibitor, E3810, versus omeprazole with diazepam in extensive and poor metabolizers of S-mephenytoin 4'-hydroxylation.
    Ishizaki T; Chiba K; Manabe K; Koyama E; Hayashi M; Yasuda S; Horai Y; Tomono Y; Yamato C; Toyoki T
    Clin Pharmacol Ther; 1995 Aug; 58(2):155-64. PubMed ID: 7648765
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interethnic difference in omeprazole's inhibition of diazepam metabolism.
    Caraco Y; Tateishi T; Wood AJ
    Clin Pharmacol Ther; 1995 Jul; 58(1):62-72. PubMed ID: 7628184
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The elimination of diazepam in Chinese subjects is dependent on the mephenytoin oxidation phenotype.
    Wan J; Xia H; He N; Lu YQ; Zhou HH
    Br J Clin Pharmacol; 1996 Oct; 42(4):471-4. PubMed ID: 8904619
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Polymorphic hydroxylation of S-mephenytoin and omeprazole metabolism in Caucasian and Chinese subjects.
    Andersson T; Regårdh CG; Lou YC; Zhang Y; Dahl ML; Bertilsson L
    Pharmacogenetics; 1992 Feb; 2(1):25-31. PubMed ID: 1302040
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pronounced differences between native Chinese and Swedish populations in the polymorphic hydroxylations of debrisoquin and S-mephenytoin.
    Bertilsson L; Lou YQ; Du YL; Liu Y; Kuang TY; Liao XM; Wang KY; Reviriego J; Iselius L; Sjöqvist F
    Clin Pharmacol Ther; 1992 Apr; 51(4):388-97. PubMed ID: 1345344
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Why are diazepam metabolism and polymorphic S-mephenytoin hydroxylation associated with each other in white and Korean populations but not in Chinese populations?
    Bertilsson L; Kalow W
    Clin Pharmacol Ther; 1993 May; 53(5):608-10. PubMed ID: 8338569
    [No Abstract]   [Full Text] [Related]  

  • 10. Lack of low Km diazepam N-demethylase in livers of poor metabolizers for S-mephenytoin 4'-hydroxylation.
    Yasumori T; Li QH; Yamazoe Y; Ueda M; Tsuzuki T; Kato R
    Pharmacogenetics; 1994 Dec; 4(6):323-31. PubMed ID: 7704038
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Stereoselective pharmacokinetics of pantoprazole, a proton pump inhibitor, in extensive and poor metabolizers of S-mephenytoin.
    Tanaka M; Ohkubo T; Otani K; Suzuki A; Kaneko S; Sugawara K; Ryokawa Y; Ishizaki T
    Clin Pharmacol Ther; 2001 Mar; 69(3):108-13. PubMed ID: 11240974
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Interethnic differences in genetic polymorphism of debrisoquin and mephenytoin hydroxylation between Japanese and Caucasian populations.
    Nakamura K; Goto F; Ray WA; McAllister CB; Jacqz E; Wilkinson GR; Branch RA
    Clin Pharmacol Ther; 1985 Oct; 38(4):402-8. PubMed ID: 4042523
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The mephenytoin oxidation polymorphism is partially responsible for the N-demethylation of imipramine.
    Skjelbo E; Brøsen K; Hallas J; Gram LF
    Clin Pharmacol Ther; 1991 Jan; 49(1):18-23. PubMed ID: 1988236
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phenotyping polymorphic drug metabolism in the French Caucasian population.
    Jacqz E; Dulac H; Mathieu H
    Eur J Clin Pharmacol; 1988; 35(2):167-71. PubMed ID: 3191936
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Metabolic disposition of pantoprazole, a proton pump inhibitor, in relation to S-mephenytoin 4'-hydroxylation phenotype and genotype.
    Tanaka M; Ohkubo T; Otani K; Suzuki A; Kaneko S; Sugawara K; Ryokawa Y; Hakusui H; Yamamori S; Ishizaki T
    Clin Pharmacol Ther; 1997 Dec; 62(6):619-28. PubMed ID: 9433390
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Metabolic disposition of imipramine in oriental subjects: relation to metoprolol alpha-hydroxylation and S-mephenytoin 4'-hydroxylation phenotypes.
    Koyama E; Sohn DR; Shin SG; Chiba K; Shin JG; Kim YH; Echizen H; Ishizaki T
    J Pharmacol Exp Ther; 1994 Nov; 271(2):860-7. PubMed ID: 7965806
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of the kinetic disposition and metabolism of E3810, a new proton pump inhibitor, and omeprazole in relation to S-mephenytoin 4'-hydroxylation status.
    Yasuda S; Horai Y; Tomono Y; Nakai H; Yamato C; Manabe K; Kobayashi K; Chiba K; Ishizaki T
    Clin Pharmacol Ther; 1995 Aug; 58(2):143-54. PubMed ID: 7648764
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Debrisoquin and S-mephenytoin hydroxylation phenotypes and CYP2D6 genotypes in an Estonian population.
    Marandi T; Dahl ML; Kiivet RA; Rägo L; Sjöqvist F
    Pharmacol Toxicol; 1996 May; 78(5):303-7. PubMed ID: 8737964
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Use of omeprazole as a probe drug for CYP2C19 phenotype in Swedish Caucasians: comparison with S-mephenytoin hydroxylation phenotype and CYP2C19 genotype.
    Chang M; Dahl ML; Tybring G; Götharson E; Bertilsson L
    Pharmacogenetics; 1995 Dec; 5(6):358-63. PubMed ID: 8747407
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of genetically determined S-mephenytoin 4-hydroxylation status and cigarette smoking on the single-dose pharmacokinetics of oral alprazolam.
    Otani K; Yasui N; Kaneko S; Ohkubo T; Osanai T; Sugawara K; Hayashi K; Chiba K; Ishizaki T
    Neuropsychopharmacology; 1997 Jan; 16(1):8-14. PubMed ID: 8981384
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.